Positiv
●
Seeking Alpha
●
vor 3 Monaten
Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.